Active 0 6 0 6 O
Hepatitis 7 16 7 16 B-chronic_disease
A 17 18 17 18 I-chronic_disease
, 18 19 18 19 O
Hepatitis 20 29 20 29 B-chronic_disease
B 30 31 30 31 I-chronic_disease
, 31 32 31 32 O
or 33 35 33 35 O
Hepatitis 36 45 36 45 B-chronic_disease
C 46 47 46 47 I-chronic_disease
infection 48 57 48 57 O

Age 0 3 58 61 B-age
≥18 4 7 62 65 O
years 8 13 66 71 I-lower_bound

Central 0 7 72 79 B-cancer
nervous 8 15 80 87 I-cancer
system 16 22 88 94 I-cancer
metastases 23 33 95 105 I-cancer
, 33 34 105 106 O
including 35 44 107 116 O
lymphomatous 45 57 117 129 B-cancer
meningitis 58 68 130 140 I-cancer

Current 0 7 141 148 O
malignancy 8 18 149 159 B-cancer
or 19 21 160 162 O
history 22 29 163 170 O
of 30 32 171 173 O
a 33 34 174 175 O
prior 35 40 176 181 O
malignancy 41 51 182 192 O
, 51 52 192 193 O
as 53 55 194 196 O
outlined 56 64 197 205 O
in 65 67 206 208 O
the 68 71 209 212 O
protocol 72 80 213 221 O

Eastern 0 7 222 229 B-clinical_variable
Cooperative 8 19 230 241 I-clinical_variable
Oncology 20 28 242 250 I-clinical_variable
Group 29 34 251 256 I-clinical_variable
( 35 36 257 258 I-clinical_variable
ECOG 36 40 258 262 I-clinical_variable
) 40 41 262 263 I-clinical_variable
performance 42 53 264 275 I-clinical_variable
status 54 60 276 282 I-clinical_variable
≤2 61 63 283 285 O

Exposure 0 8 286 294 O
to 9 11 295 297 O
chemotherapy 12 24 298 310 B-treatment
or 25 27 311 313 O
radiotherapy 28 40 314 326 B-treatment
within 41 47 327 333 O
2 48 49 334 335 O
weeks 50 55 336 341 O
( 56 57 342 343 O
6 57 58 343 344 B-lower_bound
weeks 59 64 345 350 I-lower_bound
for 65 68 351 354 O
nitrosureas 69 80 355 366 B-treatment
or 81 83 367 369 O
mitomycin 84 93 370 379 B-treatment
C 94 95 380 381 I-treatment
) 95 96 381 382 O
prior 97 102 383 388 O
to 103 105 389 391 O
entering 106 114 392 400 O
the 115 118 401 404 O
study 119 124 405 410 O
or 125 127 411 413 O
those 128 133 414 419 O
who 134 137 420 423 O
have 138 142 424 428 O
not 143 146 429 432 O
recovered 147 156 433 442 O
from 157 161 443 447 O
adverse 162 169 448 455 O
events 170 176 456 462 O
due 177 180 463 466 O
to 181 183 467 469 O
agents 184 190 470 476 O
administered 191 203 477 489 O
more 204 208 490 494 O
than 209 213 495 499 O
2 214 215 500 501 O
weeks 216 221 502 507 O
earlier 222 229 508 515 O

History 0 7 516 523 O
of 8 10 524 526 O
allergic 11 19 527 535 O
reactions 20 29 536 545 O
to 30 32 546 548 O
Pralatrexate 33 45 549 561 B-allergy_name
or 46 48 562 564 O
Romidepsin 49 59 565 575 B-allergy_name

Hodgkin 0 7 576 583 B-cancer
's 7 9 583 585 I-cancer
Disease 10 17 586 593 I-cancer
or 18 20 594 596 O
multiple 21 29 597 605 B-cancer
myeloma 30 37 606 613 I-cancer
( 38 39 614 615 O
defined 39 46 615 622 O
by 47 49 623 625 O
World 50 55 626 631 O
Health 56 62 632 638 O
Organization 63 75 639 651 O
( 76 77 652 653 O
WHO 77 80 653 656 O
) 80 81 656 657 O
criteria 82 90 658 666 O
) 90 91 666 667 O

Multiple 0 8 668 676 B-cancer
Myeloma 9 16 677 684 I-cancer
patients 17 25 685 693 O
specified 26 35 694 703 O
in 36 38 704 706 O
the 39 42 707 710 O
protocol 43 51 711 719 O

Must 0 4 720 724 O
have 5 9 725 729 O
received 10 18 730 738 O
first 19 24 739 744 B-treatment
line 25 29 745 749 I-treatment
chemotherapy 30 42 750 762 I-treatment

No 0 2 763 765 O
other 3 8 766 771 O
investigational 9 24 772 787 B-treatment
agents 25 31 788 794 I-treatment
are 32 35 795 798 O
allowed 36 43 799 806 O

No 0 2 807 809 O
upper 3 8 810 815 O
limit 9 14 816 821 O
for 15 18 822 825 O
the 19 22 826 829 O
number 23 29 830 836 O
of 30 32 837 839 O
prior 33 38 840 845 B-treatment
therapies 39 48 846 855 I-treatment

Nursing 0 7 856 863 O
women 8 13 864 869 B-gender

Patient 0 7 870 877 O
known 8 13 878 883 O
to 14 16 884 886 O
be 17 19 887 889 O
Human 20 25 890 895 B-chronic_disease
Immunodeficiency 26 42 896 912 I-chronic_disease
Virus 43 48 913 918 I-chronic_disease
( 49 50 919 920 I-chronic_disease
HIV)-positive 50 63 920 933 I-chronic_disease

Patients 0 8 934 942 O
must 9 13 943 947 O
have 14 18 948 952 O
histologically 19 33 953 967 O
confirmed 34 43 968 977 O
relapsed 44 52 978 986 O
or 53 55 987 989 O
refractory 56 66 990 1000 B-chronic_disease
Non 67 70 1001 1004 I-chronic_disease
- 70 71 1004 1005 I-chronic_disease
Hodgkin 71 78 1005 1012 I-chronic_disease
's 78 80 1012 1014 I-chronic_disease
lymphoma 81 89 1015 1023 I-chronic_disease

Patients 0 8 1024 1032 O
must 9 13 1033 1037 O
have 14 18 1038 1042 O
histologically 19 33 1043 1057 O
confirmed 34 43 1058 1067 O
relapsed 44 52 1068 1076 O
or 53 55 1077 1079 O
refractory 56 66 1080 1090 O
T 67 68 1091 1092 B-cancer
- 68 69 1092 1093 I-cancer
Cell 69 73 1093 1097 I-cancer
Lymphoma 74 82 1098 1106 I-cancer
( 83 84 1107 1108 O
as 84 86 1108 1110 O
defined 87 94 1111 1118 O
by 95 97 1119 1121 O
WHO 98 101 1122 1125 O
criteria 102 110 1126 1134 O
) 110 111 1134 1135 O

Pregnant 0 8 1136 1144 B-pregnancy
women 9 14 1145 1150 B-gender

Prior 0 5 1151 1156 B-treatment
Therapy 6 13 1157 1164 I-treatment

Systemic 0 8 1165 1173 B-treatment
steroids 9 17 1174 1182 I-treatment
that 18 22 1183 1187 O
have 23 27 1188 1192 O
not 28 31 1193 1196 O
been 32 36 1197 1201 O
stabilized 37 47 1202 1212 O
to 48 50 1213 1215 O
the 51 54 1216 1219 O
equivalent 55 65 1220 1230 O
of 66 68 1231 1233 O
≤10 69 72 1234 1237 O
mg 73 75 1238 1240 I-upper_bound
/ 75 76 1240 1241 I-upper_bound
day 76 79 1241 1244 I-upper_bound
prednisone 80 90 1245 1255 B-treatment
prior 91 96 1256 1261 O
to 97 99 1262 1264 O
the 100 103 1265 1268 O
start 104 109 1269 1274 O
of 110 112 1275 1277 O
the 113 116 1278 1281 O
study 117 122 1282 1287 O
drugs 123 128 1288 1293 O

